Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IXK0
UPID:
PHC2_HUMAN
Alternative names:
Early development regulatory protein 2
Alternative UPACC:
Q8IXK0; A1L4Q1; A8KA40; D3DPR2; Q2TAL3; Q5T0C1; Q6NUJ6; Q6ZQR1; Q8N306; Q8TAG8; Q96BL4; Q9Y4Y7
Background:
Polyhomeotic-like protein 2, also known as Early development regulatory protein 2, plays a crucial role in gene regulation. As part of the Polycomb group (PcG) multiprotein PRC1-like complex, it is essential for maintaining genes in a transcriptionally repressive state. This includes pivotal Hox genes during development. The protein's function involves chromatin remodeling and histone modification, specifically monoubiquitination of histone H2A 'Lys-119'.
Therapeutic significance:
Understanding the role of Polyhomeotic-like protein 2 could open doors to potential therapeutic strategies.